GlassScriptPhysician profile
Arkady Gendelman
NPI 1104839620
$15,097.11
in general payments reported to CMS, 2019-2025
44 companies · $2,392 in 2025
The $2,392 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,164 · 2020: $1,190 · 2021: $2,604 · 2022: $1,356 · 2023: $1,739 · 2024: $2,651 · 2025: $2,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,757.63 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,975.68 | 2019-2025 | |
| Lilly USA, LLC | $1,964.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,138.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,118.17 | 2019-2024 | Jardiance |
| Amgen INC. | $1,060.15 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $785.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $663.06 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $615.28 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Pfizer INC. | $585.20 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $554.38 | 2019-2022 | |
| Glaxosmithkline, LLC. | $440.85 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $403.96 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $381.83 | 2019-2021 | |
| Optinose US, INC. | $348.94 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $292.36 | 2020-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arkady Gendelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.